Francesca Lawson

4.4k total citations · 2 hit papers
19 papers, 3.2k citations indexed

About

Francesca Lawson is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Francesca Lawson has authored 19 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 7 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Surgery. Recurrent topics in Francesca Lawson's work include Diabetes Treatment and Management (7 papers), Cardiovascular Function and Risk Factors (5 papers) and Nausea and vomiting management (4 papers). Francesca Lawson is often cited by papers focused on Diabetes Treatment and Management (7 papers), Cardiovascular Function and Risk Factors (5 papers) and Nausea and vomiting management (4 papers). Francesca Lawson collaborates with scholars based in United States, Canada and Italy. Francesca Lawson's co-authors include Hertzel C. Gerstein, Scott D. Solomon, Eldrin F. Lewis, John J.V. McMurray, Aldo P. Maggioni, Matthew C. Riddle, Lars Køber, Rafael Díaz, Marc A. Pfeffer and Jean‐Claude Tardif and has published in prestigious journals such as New England Journal of Medicine, Blood and Cancer.

In The Last Decade

Francesca Lawson

19 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

2015 1.7k citations Marc A. Pfeffer, Brian Claggett et al. New England Journal of Medicine profile →
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

2012 382 citations Ajay K. Kakkar, Winfield S. Fisher et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francesca Lawson United States	13	1.9k	1.2k	808	738	431	19	3.2k
Anders Hvelplund Denmark	17	560 0.3×	812 0.7×	282 0.3×	1.5k 2.1×	157 0.4×	28	2.4k
George Sokos United States	15	1.2k 0.6×	979 0.8×	542 0.7×	1.6k 2.1×	67 0.2×	59	3.1k
Cezar Staniloae United States	19	418 0.2×	681 0.6×	348 0.4×	783 1.1×	97 0.2×	57	2.1k
Patrick Ohlmann France	30	290 0.2×	885 0.7×	348 0.4×	2.0k 2.7×	249 0.6×	144	3.1k
Thomas Wiegmann United States	23	642 0.3×	250 0.2×	258 0.3×	1.1k 1.4×	50 0.1×	60	2.2k
C. B. Granger United States	24	767 0.4×	598 0.5×	243 0.3×	3.6k 4.9×	543 1.3×	42	4.2k
Christian Jonasson Norway	19	645 0.3×	502 0.4×	340 0.4×	332 0.4×	98 0.2×	39	1.6k
Jacek Małyszko Poland	27	177 0.1×	438 0.4×	444 0.5×	369 0.5×	83 0.2×	163	2.6k
Lars Johansson Sweden	17	647 0.3×	353 0.3×	371 0.5×	427 0.6×	159 0.4×	43	1.3k
Masami Kosuge Japan	34	491 0.3×	1.2k 1.0×	228 0.3×	2.5k 3.4×	221 0.5×	200	3.6k

Countries citing papers authored by Francesca Lawson

Since Specialization

Citations

This map shows the geographic impact of Francesca Lawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Lawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Lawson more than expected).

Fields of papers citing papers by Francesca Lawson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Lawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Lawson. The network helps show where Francesca Lawson may publish in the future.

Co-authorship network of co-authors of Francesca Lawson

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Lawson. A scholar is included among the top collaborators of Francesca Lawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Lawson. Francesca Lawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Cotter, Gad, Beth A. Davison, Philip Janiak, et al.. (2024). Observational Study for Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure (EVOLUTION). European Journal of Heart Failure. 27(2). 325–336. 2 indexed citations

2.

Januzzi, James L., Javed Butler, Stefano Del Prato, et al.. (2022). Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. American Heart Journal. 256. 25–36. 18 indexed citations

3.

Shin, Sung‐Hee, Brian Claggett, Marc A. Pfeffer, et al.. (2020). Hyperglycaemia, Ejection Fraction and the Risk of Heart Failure or Cardiovascular Death in Patients with Type 2 Diabetes and a Recent Acute Coronary Syndrome. European Journal of Heart Failure. 22(7). 1133–1143. 10 indexed citations

4.

Perfetti, Riccardo, et al.. (2019). Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy. Journal of Cardiac Failure. 25(8). S77–S77. 2 indexed citations

5.

Seferović, Jelena P., Rhonda Bentley–Lewis, Brian Claggett, et al.. (2018). Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. Journal of Diabetes Research. 2018. 1–9. 30 indexed citations

6.

Lorenz, M., Francesca Lawson, David R. Owens, et al.. (2017). Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovascular Diabetology. 16(1). 6–6. 113 indexed citations

7.

Wolsk, Emil, Brian Claggett, Marc A. Pfeffer, et al.. (2017). Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Journal of the American Heart Association. 6(6). 77 indexed citations

8.

Bentley–Lewis, Rhonda, David Aguilar, Matthew C. Riddle, et al.. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 169(5). 631–638.e7. 79 indexed citations

9.

Pfeffer, Marc A., Brian Claggett, Rafael Díaz, et al.. (2015). Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 373(23). 2247–2257. 1726 indexed citations breakdown →

10.

Pfeffer, Marc A., Brian Claggett, Rafael Díaz, et al.. (2015). Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 373(23). 2247–2257. 56 indexed citations

11.

Kakkar, Ajay K., Giancarlo Agnelli, Winfield S. Fisher, et al.. (2013). Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery. Annals of Surgery. 259(6). 1073–1079. 28 indexed citations

12.

Kakkar, Ajay K., Winfield S. Fisher, Michael R. Lassen, et al.. (2012). Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. New England Journal of Medicine. 366(7). 601–609. 382 indexed citations breakdown →

13.

Agnelli, Giancarlo, W. D. Fisher, A.K. Kakkar, et al.. (2011). 3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups. European Journal of Cancer. 47. S222–S222. 5 indexed citations

14.

George, Daniel J., Giancarlo Agnelli, Winfield S. Fisher, et al.. (2011). Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO. Blood. 118(21). 206–206. 47 indexed citations

15.

Diemunsch, Pierre, Tong J. Gan, B. K. Philip, et al.. (2007). Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery †. British Journal of Anaesthesia. 99(2). 202–211. 119 indexed citations

16.

Diemunsch, Pierre, Tong J. Gan, Manoel Joâo Batista Castello Girão, et al.. (2006). Prevention of postoperative nausea and vomiting (PONV) following open abdominal surgery: A double-blind, multicenter comparison of the NK1 receptor antagonist aprepitant with ondansetron.. European Journal of Anaesthesiology. 23(Supplement 37). 159–159. 1 indexed citations

17.

Carides, Alexandra D., et al.. (2003). Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting. Cancer. 97(12). 3090–3098. 459 indexed citations

18.

Gralla, Richard J., Paul J. Hesketh, Steven M. Grunberg, et al.. (2003). O-249 Evaluation of the efficacy and tolerability of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: two randomized, double-blind, placebo controlled trials. Lung Cancer. 41. S73–S73. 3 indexed citations

19.

Lawson, Francesca, et al.. (2000). Standing Orders for Influenza Vaccination Increased Vaccination Rates in Inpatient Settings Compared With Community Rates. The Journals of Gerontology Series A. 55(9). M522–M526. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact